Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors (NCT02600156) | Clinical Trial Compass
CompletedNot Applicable
Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
United States7 participantsStarted 2015-09-01
Plain-language summary
The primary purpose of this study is to evaluate the feasibility and safety of MRI-guided focal laser ablation (Laser-Induced Interstitial Thermal Therapy, LITT) to treat low-risk native prostate cancer.
Who can participate
Age range45 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Male, 45 years of age or older.
* Diagnosis of prostate adenocarcinoma.
* Clinical stage T1c or T2a.
* Gleason score of 7 (3+4 or 4+3) or Intermediate risk Gleason 6
* PSA less than or equal to 20 ng/mL
* Three or fewer biopsy locations with prostate cancer which correlate with MRI findings.
* No lesion \> or = 2cm
* One, two, or three tumor suspicious regions identified on multiparametric MRI
* No definite radiographic indication of extra-capsular extension.
* Estimated survival of 5 years or greater, as determined by treating physician.
* Tolerance for anesthesia/sedation.
* Ability to give informed consent.
Exclusion Criteria
* Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.
* History of other primary non-skin malignancy within previous three years.